OR WAIT null SECS
September 30, 2021
The new LabVantage Enterprise SaaS adds full configurability and custom interfacing capabilities.
NewAge Industries has completed a plant expansion that added new cleanrooms to its headquarters in Southampton, Pa.
Gyros’ new titer kit identifies adeno-associated virus serotype 9 in vector-based cell and gene therapy manufacturing.
FDA granted orphan drug designation to Catalyst Biosciences’ MarzAA for the treatment of Factor VII Deficiency.
FDA approved AbbVie’s Qulipta (atogepant) as a preventative migraine treatment.
September 29, 2021
USP is publishing the analytics-focused chapter, which considers validation activities, in advance of the official publication.
CuriRx’s CuriLytics platform is a mass spectrometry instrument that will support complex biotherapeutics development.
GeneTx Biotherapeutics and Ultragenyx Pharmaceutical announced that FDA has removed the clinical hold on GTX-102, an investigational treatment for Angelman syndrome.
KSL Biomedical announced their expansion into Canada with the acquisition of Pulse Scientific and the incorporation of KSL Biomedical Canada.
According to Charles River Laboratories, when asked how long it takes for a drug to be developed and approved for market in the United States, only 10% of 1,500 Americans polled correctly estimated that it takes between 10 and 15 years.